Relevance of Aβ1-42 intrahippocampal injection as an animal model of inflamed Alzheimer's disease brain

Current Alzheimer Research

Volumn 5, Issue 5, 2008, Pages 475-480

  McLarnon, James G ^a   Ryu, Jae K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

A 1 42 injection animal model; Alzheimer's disease; Amyloid peptide (A 1 42); Inflammatory reactivity; Pharmacological modulations

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; CELL VIABILITY; COGNITION; DISEASE MODEL; INFLAMMATION; MICROGLIA; NERVE FUNCTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HIPPOCAMPUS; PATHOLOGY; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; INFLAMMATION; PEPTIDE FRAGMENTS; RATS;

EID: 53549105823     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508785908874     Document Type: Review

References (36)

1. Duff H and Suleman F. Transgenic mouse models of Alzheimer's disease: How useful have they been for therapeutic development. Briefings in functional genomics and proteomics 3:47-59 (2004).
2. McGowan E, Eriksen J and Hutton M. A decade of modeling close Alzheimer's disease in transgenic mice. Trends Genet 22:281-289 (2006).
3. Schwab C, Hosokawa M and McGeer PL. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer's disease. Exp Neurol 188:52-64 (2004).
4. Yamada K and Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacology & Therapeutics 88:93-113 (2000).
5. Stephan A and Phillips AG. A case for a non-transgenic animal model of Alzheimer's disease. Genes, Brain and Behavior 4:157-172 (2005).
6. Van Dam D and De Deyn PP. Drug discovery in dementia: the role of rodent models. Nature 5:956-970 (2006).
7. Sipos E, Kurunczi A, Kasza A, Horvath J, Felszeghy K, Laroche S, et al. β-amyloid pathology in the entrohinal cortex of rats induces memory deficits: implications for Alzheimer's disease. Neuroscience 147:8-36 (2007).
8. Dinamarca MC, Cerpa W, Garrido J, Hancke JL and Inestrosa NC. Hyperforin prevents βamyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-β-deposits. Mol Psychiatry 11:1032-1048 (2006).
9. (1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levels. Exp Neurol 210:164-171 (2008).
10. O'hare E, Weldon DT, Mantyh PW, Ghilardi JR, Finke MP, Kuskowski MA, et al. Delayed behavioral effects following intrahippocampal injection of aggregated A beta (1-42). Brain Res 815:1-10 (1999).
11. Boyd-Kimball D, Sultana R, Poon HF, Lynn BC and Casamenti F. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid β-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 132:313-324 (2005).
12. Liu RY, Gu R, Qi XL, Zhang T, Zhao Y, He Y, et al. Decreased nicotinic receptors and cognitive deficit in rats intracerebroventricularly injected with beta-amyloid peptide (1-42) and fed a highcholesterol diet. J Neurosci Res 86:183-193 (2008).
13. Yamada K, Tanaka T, Han D, Senzaki K, Kameyama T and Nabeshima T. Protective effects of idebenone and a-tocopherol on β-amyloid-(1-42)- induced learning and memory deficits in rats: implication of oxidative stress in β-amyloid-induced neurotoxicity in vivo. Eur J Neurosci 11:83-90(1999).
14. Jhoo JH, Kim HC, Nabeshima T, Yamada K, Shin EJ, Jhoo WK, et al. β-amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behavioural Brain Res 155:185-196 (2004).
15. 1-42 in the rat hippocampus in vivo. Neuropharmacology 52:136-145 (2007).
16. Minogue AM, Schmid AW, Fogarty MP, Moore AC, Campbell VA, Herron CE, et al. Activation of the c-Jun N-terminal kinase signaling cascade mediates the effect of amyloid-β on long term potentiation and cell death in hippocampus. J Biol Chem 278:27971-27980(2003).
17. Minogue AM, Lynch AM, Loane DJ, Herron CE and Lynch MA. Modulation of amyloid-β-induced and age-associated changes in rat hippocampus by eicosapentaenoic acid. J Neurochem 103:914-926 (2007).
18. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, et al. Intracerebroventricular injection of naturally secreted human Abeta inhibited long-term potentiation (LTP), a correlate of learning and memory, in rat hippocampus in vivo. Nature Med 11:556-561 (2005).
19. Craft JM, Watterson DM, Frautschy SA and Van Eldik LJ. Aminopyridazines inhibit β-amyloid-induced glial activation and neuronal damage in vivo. Neurobiol Aging 25:1283-1292 (2004)
20. Ralay Ranaivo H, Craft JM, Hu W, Guo L, Wing LK, Van Eldik LJ, et al. Glia as a therapeutic target: selective suppression of human amyloid-β-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 26:662-670 (2006).
21. Munoz L, Ralay Ranaivo H, Roy SM, Hu W, Craft JM, McNamara LK, et al. A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflamm 4:21 (2007).
22. Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, et al. P-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis 11:257-274 (2002).
23. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, et al. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to β-amyloid fibrils. Am J Pathol 160:101-112 (2002).
24. El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, et al. CD36 mediates the innate host response to β-amyloid. J Exp Med 197:1657-1666 (2003).
25. Ryu JK and McLarnon JG. Minocycline or iNOS inhibition block 3-nitrotyrosine increases and blood-brain barrier leakiness in amyloid beta-peptide-injected rat hippocampus. Exp Neurol 198:552-557 (2006).
26. 1-42-induced cell signaling and functional responses in human microglia. J Neurosci 26:11652-11664 (2006).
27. Ryu JK and McLarnon JG. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-α in an animal model of inflamed Alzheimer's disease brain. Neurobiol Dis 29:254-266 (2008).
28. Koenigsknecht J and Landreth G. Microglial phagocytosis of fibrillar beta-amyloid through a beta I integrin-dependent mechanism. J Neurosci 24:9838-9846 (2004).
29. McLarnon JG, Ryu JK, Walker DG and Choi HB. Upregulated expression of purinergic P2X7 receptor in Alzheimer disease and amyloid-β peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropath Exp Neurol 65:1090-109 (2006).
30. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al., Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421 (2000).
31. Rogers J, Strohmeyer R, Kovelowski CJ and Li R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia 40:260-269 (2002).
32. McGeer EG and McGeer PL. Inflammatory processes in Alzheimer's disease. Prog Neuro-Psychopharmacol Biol Psychiatry 27:741-749(2003).
33. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response. Nature Med 12:1005-1015 (2006).
34. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet 3:184-190 (2004).
35. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28:202-208 (2005).
36. Gonzalo-Ruiz A, Perez JL, Sanz JM, Geula C and Arevalo J. Effects of lipids and aging on the neurotoxicity loss caused by intracerebral injections of the amyloid-β peptide in the rat. Exp Neurol 197:41-55(2006).